The “Dyskinesia Pipeline Insight 2023” report from DelveInsight offers an in-depth analysis of the dyskinesia treatment landscape, highlighting 40+ companies and 45+ pipeline drugs ranging from clinical to nonclinical stages. Significant updates include a phase 2 study by Intra-Cellular Therapeutics for lenrispodun in August 2023, and a phase 3 trial for Teva’s TEV-50717 in September 2023, focusing on efficacy and safety for patients with dyskinesia.

Reference: DelveInsight Business Research LLP. Dyskinesia Pipeline, Clinical Trials, Emerging Therapies, and FDA Approvals 2023 (Updated). Open PR Worldwide Public Relations. Published October 27, 2023. Accessed November 8, 2023. https://www.openpr.com/news/3266872/dyskinesia-pipeline-clinical-trials-emerging-therapies